Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Analysts at Leerink Partnrs cut their Q1 2025 earnings per share estimates for shares of Aura Biosciences in a research note issued on Tuesday, April 8th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.55) per share for the quarter, down from their prior estimate of ($0.49). The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences' Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.35) EPS and FY2026 earnings at ($2.72) EPS.
Other research analysts have also recently issued reports about the stock. HC Wainwright set a $25.00 price target on shares of Aura Biosciences in a report on Tuesday, March 25th. Citigroup reissued an "outperform" rating on shares of Aura Biosciences in a research report on Wednesday, March 26th. JMP Securities set a $19.00 target price on Aura Biosciences in a report on Wednesday, March 26th. Finally, Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $22.75.
Check Out Our Latest Report on AURA
Aura Biosciences Stock Down 2.5 %
AURA traded down $0.14 during midday trading on Friday, hitting $5.43. The company had a trading volume of 58,718 shares, compared to its average volume of 199,819. The company has a market capitalization of $272.72 million, a price-to-earnings ratio of -3.14 and a beta of 0.43. The stock's 50 day moving average price is $6.85 and its 200 day moving average price is $8.23. Aura Biosciences has a 52 week low of $3.40 and a 52 week high of $12.38.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09).
Institutional Investors Weigh In On Aura Biosciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in shares of Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock valued at $1,233,000 after purchasing an additional 3,612 shares in the last quarter. State Street Corp boosted its holdings in Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company's stock valued at $6,725,000 after acquiring an additional 26,841 shares during the period. Wellington Management Group LLP purchased a new position in Aura Biosciences in the third quarter valued at $1,037,000. Barclays PLC grew its holdings in Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock worth $544,000 after acquiring an additional 43,897 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock worth $8,990,000 after acquiring an additional 39,379 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 23,045 shares of company stock valued at $177,242 in the last ninety days. Insiders own 5.40% of the company's stock.
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Stories
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
